C4 Therapeutics, Inc. shareholder update: a group of Soleus investment entities filed an amended Schedule 13G/A reporting passive ownership of C4 Therapeutics common stock.
Soleus Capital Management, L.P., Soleus GP, LLC and Guy Levy each report beneficial ownership of 10,334,114 shares, representing 9.99% of the outstanding common stock based on 96,914,418 shares as of October 29, 2025. This total includes warrants to purchase up to 6,530,172 shares, subject to beneficial ownership limitations in those warrants. Other Soleus entities, including Soleus Private Equity Fund III, L.P., report 6,072,822 shares, or 5.9% of the class, including warrants to purchase up to 5,822,829 shares.
The filing states the securities were not acquired and are not held for the purpose of changing or influencing control of C4 Therapeutics, and multiple Soleus entities and Guy Levy disclaim beneficial ownership beyond Section 13(d) reporting obligations.
Positive
None.
Negative
None.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)
C4 Therapeutics, Inc
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
12529R107
(CUSIP Number)
12/31/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
12529R107
1
Names of Reporting Persons
Soleus Private Equity Fund III, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
6,072,822.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
6,072,822.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
6,072,822.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.9 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: (1) The shares reported in the table above are held directly by Soleus Private Equity Fund III, L.P. ("Soleus PE"). Soleus Private Equity GP III, LLC ("Soleus PE GP") is the sole general partner of Soleus PE, Soleus PE GP III, LLC is the sole manager of Soleus PE GP, Soleus Capital Management, L.P. ("SCM") is the investment manager for Soleus PE and for Soleus Capital Master Fund, L.P. ("Master Fund"), and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of Soleus PE GP III, LLC and of Soleus GP, LLC. Each of Mr. Levy, Soleus PE GP III, LLC, Soleus PE GP, SCM and Soleus GP, LLC disclaims beneficial ownership of these shares held by Soleus PE other than for the purpose of determining their obligations under Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose.
(2) The number of shares reported in the table above includes warrants to purchase up to 5,822,829 shares of the common stock of C4 Therapeutics, Inc. (the "Issuer").
(3) The percentage set forth in row 11 is calculated based upon 96,914,418 shares of the common stock of the Issuer outstanding as of October 29, 2025, as reported on the cover of the Issuer's Quarterly Report on Form 10-Q for the period ended September 30, 2025 filed with the Securities and Exchange Commission on November 6, 2025 (the "Form 10-Q").
SCHEDULE 13G
CUSIP No.
12529R107
1
Names of Reporting Persons
Soleus Private Equity GP III, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
6,072,822.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
6,072,822.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
6,072,822.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.9 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: (1) The shares reported in the table above are held directly by Soleus PE. Soleus PE GP is the sole general partner of Soleus PE, Soleus PE GP III, LLC is the sole manager of Soleus PE GP, SCM is the investment manager for Soleus PE and for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of Soleus PE GP III, LLC and of Soleus GP, LLC. Each of Mr. Levy, Soleus PE GP III, LLC, Soleus PE GP, SCM and Soleus GP, LLC disclaims beneficial ownership of these shares held by Soleus PE other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose.
(2) The number of shares reported in the table above includes warrants to purchase up to 5,822,829 shares of the common stock of the Issuer.
(3) The percentage set forth in row 11 is calculated based upon 96,914,418 shares of the common stock of the Issuer outstanding as of October 29, 2025, as set forth on the cover of the Form 10-Q.
SCHEDULE 13G
CUSIP No.
12529R107
1
Names of Reporting Persons
Soleus PE GP III, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
6,072,822.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
6,072,822.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
6,072,822.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.9 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: (1) The shares reported in the table above are held directly by Soleus PE. Soleus PE GP is the sole general partner of Soleus PE, Soleus PE GP III, LLC is the sole manager of Soleus PE GP, SCM is the investment manager for Soleus PE and for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of Soleus PE GP III, LLC and of Soleus GP, LLC. Each of Mr. Levy, Soleus PE GP III, LLC, Soleus PE GP, SCM and Soleus GP, LLC disclaims beneficial ownership of these shares held by Soleus PE other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose.
(2) The number of shares reported in the table above includes warrants to purchase up to 5,822,829 shares of the common stock of the Issuer.
(3) The percentage set forth in row 11 is calculated based upon 96,914,418 shares of the common stock of the Issuer outstanding as of October 29, 2025, as set forth on the cover of the Form 10-Q.
SCHEDULE 13G
CUSIP No.
12529R107
1
Names of Reporting Persons
Soleus Capital Master Fund, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
10,361,860.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
10,361,860.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
10,361,860.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
FI
Comment for Type of Reporting Person: (1) The shares reported in the table above are held directly by Master Fund. Soleus Capital, LLC is the sole general partner of Master Fund, Soleus Capital Group, LLC ("SCG") is the sole managing member of Soleus Capital, LLC, SCM is the investment manager for Soleus PE and for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of SCG and of Soleus GP, LLC. Each of SCG, Soleus Capital, LLC, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose.
(2) The number of shares reported in the table above includes warrants to purchase up to 6,807,911 shares of the common stock of the Issuer, and reflects the maximum number of shares of common stock that may be held by the Reporting Person as a result of the beneficial ownership limitations set forth in such warrants.
(3) The percentage set forth in row 11 is calculated based upon 96,914,418 shares of the common stock of the Issuer outstanding as of October 29, 2025, as set forth on the cover of the Form 10-Q.
SCHEDULE 13G
CUSIP No.
12529R107
1
Names of Reporting Persons
Soleus Capital, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
10,361,860.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
10,361,860.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
10,361,860.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: (1) The shares reported in the table above are held directly by Master Fund. Soleus Capital, LLC is the sole general partner of Master Fund, SCG is the sole managing member of Soleus Capital, LLC, SCM is the investment manager for Soleus PE and for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of SCG and of Soleus GP, LLC. Each of SCG, Soleus Capital, LLC, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose.
(2) The number of shares reported in the table above includes warrants to purchase up to 6,807,911 shares of the common stock of the Issuer, and reflects the maximum number of shares of common stock that may be held by the Reporting Person as a result of the beneficial ownership limitations set forth in such warrants.
(3) The percentage set forth in row 11 is calculated based upon 96,914,418 shares of the common stock of the Issuer outstanding as of October 29, 2025, as set forth on the cover of the Form 10-Q.
SCHEDULE 13G
CUSIP No.
12529R107
1
Names of Reporting Persons
Soleus Capital Group, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
10,361,860.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
10,361,860.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
10,361,860.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: (1) The shares reported in the table above are held directly by Master Fund. Soleus Capital, LLC is the sole general partner of Master Fund, SCG is the sole managing member of Soleus Capital, LLC, SCM is the investment manager for Soleus PE and for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of SCG and of Soleus GP, LLC. Each of SCG, Soleus Capital, LLC, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose.
(2) The number of shares reported in the table above includes warrants to purchase up to 6,807,911 shares of the common stock of the Issuer, and reflects the maximum number of shares of common stock that may be held by the Reporting Person as a result of the beneficial ownership limitations set forth in such warrants.
(3) The percentage set forth in row 11 is calculated based upon 96,914,418 shares of the common stock of the Issuer outstanding as of October 29, 2025, as set forth on the cover of the Form 10-Q.
SCHEDULE 13G
CUSIP No.
12529R107
1
Names of Reporting Persons
Soleus Capital Management, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
10,334,114.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
10,334,114.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
10,334,114.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: (1) The shares reported in the table above are held directly by Soleus PE and by Master Fund. Soleus PE GP is the sole general partner of Soleus PE, Soleus PE GP III, LLC is the sole manager of Soleus PE GP, SCM is the investment manager for Soleus PE, and Soleus GP, LLC is the sole general partner of SCM. Soleus Capital, LLC is the sole general partner of Master Fund, SCG is the sole managing member of Soleus Capital, LLC, SCM is the investment manager for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of Soleus PE GP III, LLC, SCG and Soleus GP, LLC. Each of Soleus PE GP, Soleus PE GP III, LLC, Soleus Capital, LLC, SCG, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held directly by Soleus PE and Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose.
(2) The number of shares reported in the table above includes warrants to purchase up to 6,530,172 shares of the common stock of the Issuer, and reflects the maximum number of shares of common stock that may be held by the Reporting Person as a result of the beneficial ownership limitations set forth in such warrants.
(3) The percentage set forth in row 11 is calculated based upon 96,914,418 shares of the common stock of the Issuer outstanding as of October 29, 2025, as set forth on the cover of the Form 10-Q.
SCHEDULE 13G
CUSIP No.
12529R107
1
Names of Reporting Persons
Soleus GP, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
10,334,114.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
10,334,114.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
10,334,114.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: (1) The shares reported in the table above are held directly by Soleus PE and by Master Fund. Soleus PE GP is the sole general partner of Soleus PE, Soleus PE GP III, LLC is the sole manager of Soleus PE GP, SSCM is the investment manager for Soleus PE, and Soleus GP, LLC is the sole general partner of SCM. Soleus Capital, LLC is the sole general partner of Master Fund, SCG is the sole managing member of Soleus Capital, LLC, SCM is the investment manager for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of Soleus PE GP III, LLC, SCG and Soleus GP, LLC. Each of Soleus PE GP, Soleus PE GP III, LLC, Soleus Capital, LLC, SCG, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held directly by Soleus PE and Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose.
(2) The number of shares reported in the table above includes warrants to purchase up to 6,530,172 shares of the common stock of the Issuer, and reflects the maximum number of shares of common stock that may be held by the Reporting Person as a result of the beneficial ownership limitations set forth in such warrants.
(3) The percentage set forth in row 11 is calculated based upon 96,914,418 shares of the common stock of the Issuer outstanding as of October 29, 2025, as set forth on the cover of the Form 10-Q.
SCHEDULE 13G
CUSIP No.
12529R107
1
Names of Reporting Persons
Guy Levy
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
10,334,114.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
10,334,114.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
10,334,114.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: (1) The shares reported in the table above are held directly by Soleus PE and by Master Fund. Soleus PE GP is the sole general partner of Soleus PE, Soleus PE GP III, LLC is the sole manager of Soleus PE GP, SCM is the investment manager for Soleus PE, and Soleus GP, LLC is the sole general partner of SCM. Soleus Capital, LLC is the sole general partner of Master Fund, SCG is the sole managing member of Soleus Capital, LLC, SCM is the investment manager for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of Soleus PE GP III, LLC, SCG and Soleus GP, LLC. Each of Soleus PE GP, Soleus PE GP III, LLC, Soleus Capital, LLC, SCG, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held directly by Soleus PE and Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose.
(2) The number of shares reported in the table above includes warrants to purchase up to 6,530,172 shares of the common stock of the Issuer, and reflects the maximum number of shares of common stock that may be held by the Reporting Person as a result of the beneficial ownership limitations set forth in such warrants.
(3) The percentage set forth in row 11 is calculated based upon 96,914,418 shares of the common stock of the Issuer outstanding as of October 29, 2025, as set forth on the cover of the Form 10-Q.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
C4 Therapeutics, Inc
(b)
Address of issuer's principal executive offices:
490 Arsenal Way, Suite 120, Watertown, MA 02472
Item 2.
(a)
Name of person filing:
Soleus Private Equity GP III, LLC
Soleus Private Equity Fund III, L.P.
Soleus PE GP III, LLC
Soleus Capital Master Fund, L.P.
Soleus Capital, LLC
Soleus Capital Group, LLC
Soleus Capital Management, L.P.
Soleus GP, LLC
Guy Levy
(b)
Address or principal business office or, if none, residence:
Soleus Private Equity GP III, LLC
100 Field Point Road, Suite 200
Greenwich, CT 06830
Soleus Private Equity Fund III, L.P.
100 Field Point Road, Suite 200
Greenwich, CT 06830
Soleus PE GP III, LLC
100 Field Point Road, Suite 200
Greenwich, CT 06830
Soleus Capital Master Fund, L.P.
100 Field Point Road, Suite 200
Greenwich, CT 06830
Soleus Capital, LLC
100 Field Point Road, Suite 200
Greenwich, CT 06830
Soleus Capital Group, LLC
100 Field Point Road, Suite 200
Greenwich, CT 06830
Soleus Capital Management, L.P.
100 Field Point Road, Suite 200
Greenwich, CT 06830
Soleus GP, LLC
100 Field Point Road, Suite 200
Greenwich, CT 06830
Guy Levy
c/o Soleus Capital Management, L.P.
100 Field Point Road, Suite 200
Greenwich, CT 06830
(c)
Citizenship:
Soleus Private Equity GP III, LLC - Delaware
Soleus Private Equity Fund III, L.P. - Delaware
Soleus PE GP III, LLC - Delaware
Soleus Capital Master Fund, L.P. - Cayman Islands
Soleus Capital, LLC - Delaware
Soleus Capital Group, LLC - Delaware
Soleus Capital Management, L.P. - Delaware
Soleus GP, LLC - Delaware
Guy Levy - United States
(d)
Title of class of securities:
Common Stock, par value $0.0001 per share
(e)
CUSIP No.:
12529R107
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information in rows 5 through 9 and 11 on the cover pages to this Schedule 13G, including the footnotes thereto, is hereby incorporated by reference.
Soleus Private Equity GP III, LLC - 6,072,822
Soleus Private Equity Fund III, L.P. - 6,072,822
Soleus PE GP III, LLC - 6,072,822
Soleus Capital Master Fund, L.P. - 10,361,860
Soleus Capital, LLC - 10,361,860
Soleus Capital Group, LLC - 10,361,860
Soleus Capital Management, L.P. - 10,334,114
Soleus GP, LLC - 10,334,114
Guy Levy - 10,334,114
(b)
Percent of class:
Soleus Private Equity GP III, LLC - 5.9%
Soleus Private Equity Fund III, L.P. - 5.9%
Soleus PE GP III, LLC - 5.9%
Soleus Capital Master Fund, L.P. - 9.99%
Soleus Capital, LLC - 9.99%
Soleus Capital Group, LLC - 9.99%
Soleus Capital Management, L.P. - 9.99%
Soleus GP, LLC - 9.99%
Guy Levy - 9.99%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
Soleus Private Equity GP III, LLC - 6,072,822
Soleus Private Equity Fund III, L.P. - 6,072,822
Soleus PE GP III, LLC - 6,072,822
Soleus Capital Master Fund, L.P. - 10,361,860
Soleus Capital, LLC - 10,361,860
Soleus Capital Group, LLC - 10,361,860
Soleus Capital Management, L.P. - 10,334,114
Soleus GP, LLC - 10,334,114
Guy Levy - 10,334,114
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
Soleus Private Equity GP III, LLC - 6,072,822
Soleus Private Equity Fund III, L.P. - 6,072,822
Soleus PE GP III, LLC - 6,072,822
Soleus Capital Master Fund, L.P. - 10,361,860
Soleus Capital, LLC - 10,361,860
Soleus Capital Group, LLC - 10,361,860
Soleus Capital Management, L.P. - 10,334,114
Soleus GP, LLC - 10,334,114
Guy Levy - 10,334,114
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
What ownership in C4 Therapeutics (CCCC) do the Soleus entities report?
The Soleus group reports up to 10,334,114 C4 Therapeutics shares, or 9.99% of the common stock, beneficially owned by Soleus Capital Management, L.P., Soleus GP, LLC and Guy Levy, based on 96,914,418 shares outstanding as of October 29, 2025.
How many C4 Therapeutics shares does Soleus Private Equity Fund III, L.P. report?
Soleus Private Equity Fund III, L.P. reports beneficial ownership of 6,072,822 C4 Therapeutics shares, representing 5.9% of the common stock. This amount includes warrants to purchase up to 5,822,829 shares of C4 Therapeutics common stock under the disclosed arrangements.
What percentage of C4 Therapeutics does Soleus Capital Master Fund, L.P. own?
Soleus Capital Master Fund, L.P. reports beneficial ownership of 10,361,860 C4 Therapeutics shares, equal to 9.99% of the company’s common stock class. This figure is calculated using 96,914,418 shares outstanding as of October 29, 2025, as disclosed in C4’s Form 10-Q.
Do the Soleus entities’ C4 Therapeutics holdings include warrants?
Yes. The reported holdings include warrants for up to 6,530,172 shares for Soleus Capital Management, L.P. and related filers, and up to 5,822,829 shares for Soleus Private Equity Fund III, L.P., subject to beneficial ownership limitations embedded in the warrant terms.
Are the Soleus entities seeking control of C4 Therapeutics (CCCC)?
The filing states the C4 Therapeutics securities were not acquired and are not held for changing or influencing control of the issuer. The group characterizes its position as passive ownership under Schedule 13G/A, consistent with the certification language provided.
How is the C4 Therapeutics ownership percentage calculated in this Schedule 13G/A?
Ownership percentages use 96,914,418 C4 Therapeutics shares outstanding as of October 29, 2025, as reported on the company’s Form 10-Q cover. Each Soleus reporting person’s percentage, such as 5.9% or 9.99%, is derived from beneficially owned shares divided by that total.
